Dec 08,2022

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.

DexCom, Inc. announced today the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all Types of diabetes ages two years and older. Dexcom is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible.

REGULATORY FDA

#cgm

#insulin pump

#telehealth

View Analyst & Ambassador Comments
Go to original news
Dec 08,2022

Omada Health is the First Virtual Care Company to Join the Institute for Healthcare Improvement Leadership Alliance

Omada Health, a virtual, integrated chronic care provider, joined the Institute for Healthcare Improvement (IHI) Leadership Alliance as its first virtual health member. The Leadership Alliance is a dynamic collaboration of health care providers united by a common mission — to work with one another and in partnership with patients, workforces, and communities to deliver the full promise of the IHI Triple Aim: improve the health of populations, enhance the experience of patients, and reduce the per capita cost of care.

#virtual care

View Analyst & Ambassador Comments
Go to original news
Dec 08,2022

BIOCORP’s Mallya smart device receives FDA 510(k) clearance

French medical devices company BIOCORP has secured 510(k) clearance for marketing its Mallya smart medical device from the US Food and Drug Administration (FDA). Mallya is a smart sensor that has been designed to be attached directly to insulin pen injectors, converting them into connected devices. It automatically records important treatment information, including selected insulin units as well as the date and time of injection, and transmits the data to a dedicated digital app.

REGULATORY FDA

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 08,2022

Vida Health’s Spanish-Language Virtual Diabetes Solution Achieves Meaningful Clinical Outcomes

New research published in JMIR Formative Research shows clinically significant Hemoglobin A1C (HbA1C) reduction for a diabetic population who used Vida Health’s Spanish solution. These clinical outcomes reinforce the importance of providing accessible care that’s adapted to fit the needs of diverse populations.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Dec 09,2022 TOP STORY

Eli Lilly discontinues Ypsomed collaboration to pursue its own U.S. insulin pump offering

Ypsomed announced today that Eli Lilly (NYSE:LLY) elected to stop their joint project to enter the U.S. insulin pump market. In November 2020, the companies entered into a commercialization agreement. The agreement entailed registering and commercializing Ypsomed’s YpsoPump under Lilly’s branding in the U.S. Ypsomed said that, over the past two years, it customized its pump for the U.S. market in preparation for commercialization. Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016.

PRODUCT

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 09,2022

NIH funds Illinois Tech project using machine learning to fully automate insulin delivery

Researchers at Illinois Institute of Technology received $1.2 million from the NIH to develop a machine learning system for an artificial pancreas’ insulin delivery. Chemical engineering professor Ali Cinar leads the project to ease the burden on those with type 1 diabetes. NIH funding covers four years for developing the machine learning system. Researchers expect the system to assign a probability to the likelihood of a person eating lunch soon based on their behavior. It then administers an insulin dose accordingly and continues to monitor glucose levels. If the levels rise as expected because a person begins eating, it administers additional insulin.

View Analyst & Ambassador Comments
Go to original news
Dec 12,2022

Dexcom Canada Partners With Green Shield and The Health Depot to Offer Plan Members a Comprehensive Digital Diabetes Care Experience

Dexcom, Inc.a announced today its partnership with Green Shield and The Health Depot digital pharmacy to provide Green Shield plan members with convenient access to the Dexcom G6 rtCGM System combined with virtual diabetes coaching support. Green Shield plan members eligible for Dexcom G6 rtCGM coverage who register for this new Digital Diabetes Care Program, delivered by The Health Depot, will have exclusive access to convenient and coordinated diabetes management support services

COLLABORATION PARTNERSHIP

#insurance

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 13,2022

Hygieia adds to team, continues rapid, national expansion of its d-Nav® Insulin Management Program

Hygieia, a digital therapeutics company, has relocated and expanded its headquarters to accommodate additional staff as it continues significant growth and pursues partnerships with endocrinology practices across the United States.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 13,2022

Diabetes Reversal Leader Virta Health Deepens Executive Bench Amid Triple-Digit Year-Over-Year Growth

Virta Health is expanding its C-suite as the company scales to meet heightened demand for its chronic disease reversal solutions. With nearly two decades of industry experience, Manu Diwakar joins as Chief Financial Officer (CFO). Before Virta, Diwakar served as CFO at virtual musculoskeletal treatment company Kaia Health.

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

The Worldwide Insulin Pen Industry is Expected to Reach $64.7 Billion by 2027

The global insulin pump market is estimated to reach US$ 64.75 Billion by 2027, US$ 50.84 Billion in 2021.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES